BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Talks.cam//talks.cam.ac.uk//
X-WR-CALNAME:Talks.cam
BEGIN:VEVENT
SUMMARY:Bigger Picture Talks\, Prof Yvonne Perrie: Designing delivery syst
 ems for mRNA vaccines - Professor Yvonne Perrie\, University of Strathclyd
 e
DTSTART:20210310T160000Z
DTEND:20210310T170000Z
UID:TALK157855@talks.cam.ac.uk
CONTACT:Communications\, CEB
DESCRIPTION:Through Bigger Picture Talks\, we are inviting thought-leaders
  from across the world\, who are driving significant advances in our impac
 t areas of energy\, health and sustainability\, to share and discuss their
  work with us.\n\nThe efficacy of RNA-based vaccines has been recently dem
 onstrated\, leading to the use of mRNA-based COVID-19 vaccines. mRNA vacci
 nes can induce potent immune responses without the need of translocation i
 nto the cell nucleus. Furthermore\, mRNA manufacturing can be optimized to
  be low-cost\, fully synthetic and scalable. mRNA vaccines are divided int
 o conventional non-amplifying mRNA and self-amplifying mRNA (samRNA) vacci
 nes and with all types\, due to their polyanionic nature and susceptible t
 o enzymatic degradation\, delivery systems are needed to facilitate the cl
 inical translation of RNA-based vaccines. To date\, lipid nanoparticles (L
 NPs) based on ionizable amino-lipids are the most advanced RNA delivery sy
 stems and this technology is now being deployed in COVID-19 vaccines. With
 in our laboratories we have investigated the impact of the delivery system
  formulation and platform and the route of administration. To achieve this
 \, we investigated the immunogenicity of a self-amplifying mRNA encoding t
 he rabies virus glycoprotein encapsulated in 3 different non-viral deliver
 y platforms (lipid nanoparticles\, solid lipid nanoparticles and polymeric
  nanoparticles). These were administered via three different routes: intra
 muscular\, intradermal and intranasal. Immunogenicity data in a mouse mode
 l showed that lipid nanoparticles and solid lipid nanoparticles induced si
 milar responses upon intramuscular and intradermal administration and comp
 arable potency with the commercial (non-RNA based) vaccine. Our results de
 monstrate that both the administration route and delivery system format di
 ctate self-amplifying RNA vaccine efficacy\, with lipid nanoparticles and 
 solid lipid nanoparticles given via either intramuscular or intradermal ro
 ute promoting the highest responses.\n\n"Please register on Zoom":https://
 zoom.us/webinar/register/WN_1fAikiZAR9iqdpCybMh-MA\n\n\nOpen to all\n\nBio
 :\nMy current position is Professor in Drug Delivery within the Strathclyd
 e Institute of Pharmacy and Biomedical Sciences\, University of Strathclyd
 e\, Glasgow\, Scotland. I qualified as a Pharmacist in 1995 and In 1998 I 
 gained my PhD from the University of London investigating the role of lipo
 somes for drug delivery. I then worked in London within a newly establishe
 d Drug Delivery Company (Lipoxen Technologies Ltd) for two years\, develop
 ing their liposome drug delivery platform technology prior to moving into 
 Academia to set up my own research group. My research is multi-disciplinar
 y and focuses on the development of drug delivery systems to facilitate th
 e delivery of drugs and vaccines\, thus providing practical solutions for 
 current healthcare problems.
LOCATION:https://zoom.us/webinar/register/WN_1fAikiZAR9iqdpCybMh-MA
END:VEVENT
END:VCALENDAR